Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 5/20 | 0.48 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 8/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 7/20 | 0.38 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.38 |
| ▸ | NPY1R | P25929 | 2/20 | 0.38 |
| ▸ | NPY4R | P50391 | 2/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.38 |
| ▸ | NPY2R | P49146 | 1/20 | 0.38 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17722931 | 1.00 | FAP (0.48) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL18393158 | 1.00 | FAP (0.48) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL14887318 | 1.00 | FAP (0.48) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL17150096 | 1.00 | FAP (0.48) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL14887245 | 0.99 | FAP (0.47) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL16645049 | 0.99 | FAP (0.47) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL26058117 | 0.97 | FAP (0.46) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL23420151 | 0.95 | FAP (0.48) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL14978945 | 0.95 | FAP (0.48) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL28365735 | 0.95 | FAP (0.48) | FAPMAP1LC3BSIRT2SIRT1SIRT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230062712-A1 | ANTI-ASGR1 ANTIBODY CONJUGATES AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230062712-A1 | ANTI-ASGR1 ANTIBODY CONJUGATES AND USES THEREOF | ASGR1, HAVCR2, FCGR2A | FAP 3499/4885MAP1LC3B 1900/4885SIRT2 3784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.